# A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

> **NCT02536911** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 24 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** eliglustat

## Key facts

- **NCT ID:** NCT02536911
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536911, "A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02536911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*